Costs per lung cancer death prevented, including medical costs and productivity losses, were:
universal screening between $3,030,000 (4 pCi/L) and $68,440,000 (20 pCi/L);
targeted screening between $2,040,000 (4 pCi/L) and $148,670,000 (20 pCi/L);
modified universal screening between $920,000 (4 pCi/L) and $2,550,000 (20 pCi/L);
modified targeted screening between $520,000 (4 pCi/L) and $9,470,000 (20 pCi/L).
Costs per life year were:
universal screening between $480,000 (4 pCi/L) and $1,440,000 (10 pCi/L);
targeted screening between $330,000 (4 pCi/L) and $730,000 (10 pCi/L);
modified universal screening between $110,000 (8 pCi/L) and $500,000 (20 pCi/L);
modified targeted screening between $70,000 (8 pCi/L) and $2,410,000 (20 pCi/L).
Performing an intervention in the homes of smokers was more cost-effective than performing one in the home of someone who had never smoked. From the first decade through the fourth decade of life, the cost-effectiveness estimates for the universal and targeted scenarios decrease, after which they progressively increase with increasing age. The cost-effectiveness results were sensitive to changes in the probabilities of retesting, of mitigating or of successfully mitigating, and costs.